Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT06924333

The Skin Microbiota in Skin Disease and Eczema

Status
Enrolling By Invitation
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Region Skane · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Background: The skin microbiota influence skin health in several skin diseases and atopic dermatitis (AD). Presence of Staphylococcus have been associated to a sever course of the disease. Objectives: The aim of the study is to investigate the influence of bacteria, and the skin microbiota on the inflammation and skin barrier. Moreover, dysbiosis in the microbiota, the inflammation profile, the skin barrier damage will be related to objective and patient oriented measures. Importance: Knowledge of interactions between host defense, skin barrier and bacterial colonizing skin can facilitate development of new prevention and treatment strategies to control microbial impact in skin diseases and eczema.

Detailed description

The role of the skin microbiome in atopic eczema and other skin diseases remains to be investigated. There are reports indicating an association of skin-colonization of Staphylococcus aureus (S. aureus) and the severity of the disease. Skin colonizing pathogens might be important cofactor for persistence of eczema and other skin diseases, as well as the commensal, non-pathogenic, microflora of the skin might have protective effects. The aim of this research project is to investigate the skin microbiome in patients with eczema and other skin diseases and elucidate the relation to skin barrier impairment and severity of the skin disease. Specifically, we will: * Determine the skin microbiome and metagenome in skin of patients with eczema and other skin diseases. * Straighten out the relationship between the skin microbiome, the skin barrier, contact allergies, quality of life, eczema control and severity in patients with eczema and other skin diseases. * Identify biological markers, such as antimicrobial peptides, cytokines and gene-expression profiles in skin, and other factors contributing to the development and persistence of eczema and other skin diseases.

Conditions

Timeline

Start date
2025-01-20
Primary completion
2026-01-20
Completion
2027-01-20
First posted
2025-04-11
Last updated
2025-04-11

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT06924333. Inclusion in this directory is not an endorsement.